Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Cipla
Boehringer Ingelheim
Citi
Johnson and Johnson

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 9,192,663

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,192,663
Title:Antibodies for epidermal growth factor receptor 3 (HER3)
Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
Inventor(s): Elis; Winfried (Munchen-Pasing, DE), Ettenberg; Seth (Melrose, MA), Garner; Andrew Paul (Arlington, MA), Haubst; Nicole (Munich, DE), Huang; Xizhong (Southborough, MA), Kunz; Christian Carsten Silvester (Munich, DE), Reisinger Sprague; Elizabeth Anne (Concord, MA), Sheng; Qing (Sharon, MA)
Assignee: NOVARTIS AG (Basel, CH)
Application Number:13/693,330
Patent Claims:see list of patent claims

Details for Patent 9,192,663

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial NOVARTIS AG (Basel, CH) 2031-12-05 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial NOVARTIS AG (Basel, CH) 2031-12-05 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Try a Free Trial NOVARTIS AG (Basel, CH) 2031-12-05 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Try a Free Trial NOVARTIS AG (Basel, CH) 2031-12-05 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Try a Free Trial NOVARTIS AG (Basel, CH) 2031-12-05 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Try a Free Trial NOVARTIS AG (Basel, CH) 2031-12-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chinese Patent Office
Fish and Richardson
Accenture
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.